Walleye Capital
AMRX icon

Walleye Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

Walleye Capital’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$315K Buy
18,199
+7,497
+70% +$103K ﹤0.01% 3135
2026
Q1 		$133K Buy
+10,702
New +$144K ﹤0.01% 3546
2025
Q4 		– Sell
-798,870
Closed -$8M – 4523
2025
Q3 		$8M Buy
798,870
+89,924
+13% +$807K 0.03% 644
2025
Q2 		$5.74M Buy
708,946
+150,104
+27% +$1.13M 0.02% 792
2025
Q1 		$4.68M Buy
558,842
+519,863
+1,334% +$4.34M 0.02% 828
2024
Q4 		$309K Sell
38,979
-92,688
-70% -$778K ﹤0.01% 3403
2024
Q3 		$1.1M Buy
+131,667
New +$1.03M ﹤0.01% 2565
2024
Q2 		– Sell
-78,098
Closed -$473K – 5549
2024
Q1 		$473K Buy
+78,098
New +$440K ﹤0.01% 3246
2020
Q1 		– Sell
-75,900
Closed -$366K – 892
2019
Q4 		$366K Buy
75,900
+35,473
+88% +$123K 0.02% 828
2019
Q3 		$117K Buy
+40,427
New +$141K 0.01% 1387
2019
Q2 		– Sell
-100
Closed -$1K – 1706
2019
Q1 		$1K Buy
+100
New +$1.32K ﹤0.01% 1465

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Walleye Capital's AMRX Position: Q2 2026 in Review

Walleye Capital increased its Amneal Pharmaceuticals (AMRX) stake by 70% in Q2 2026, buying an estimated $103K and bringing the position to 18,199 shares worth $315K. The position accounts for ﹤0.01% of the portfolio, ranked #3135.

Walleye Capital first reported a position in AMRX in Q1 2019 and has held it in 11 quarters since. The position peaked at $8M in Q3 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Walleye Capital held 18,199 shares of Amneal Pharmaceuticals worth $315K as of Q2 2026.
  • Walleye Capital bought 7,497 Amneal Pharmaceuticals shares in Q2 2026, an estimated $103K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3135 holding.
  • Walleye Capital first reported a position in Amneal Pharmaceuticals in Q1 2019 and has held it in 11 quarters since.
  • Walleye Capital's Amneal Pharmaceuticals position peaked at $8M in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.